“CMS may consider future policy options for (anti-obesity medications) pending further review of both the potential benefits of these drugs including updated clinical indications, and relevant ...

Drugs that are approved by these regulatory bodies are then considered safe for clinical use. However, historical evidence shows that approval does not guarantee long-term safety and efficacy.

The Centers for Medicare and Medicaid Services said Friday it will not finalize a rule proposed by the Biden administration to cover the drugs, saying it was "not appropriate at this time." IE 11 ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them ...

Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy. The rule was not expected to be ...

A discreet delivery pulled up outside of Idaho’s maximum-security prison near Boise in the state’s exhaustive quest for lethal injection drugs 1 1⁄2 years ago. Just outside of the prison ...

Our world has too much noise and too little context. Vox helps you understand what matters. We don’t drown you in panic-inducing headlines, and we’re not obsessed with being the first to break ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

Laila Maidan is a Tech and Investing reporter at MarketWatch. She covers the rapid developments in the sector along with actionable investment recommendations and deep dives into valuations.